Australia's most trusted
source of pharma news
Posted 20 February 2025 PM
As the high stakes contest to win the multibillion-dollar obesity and diabetes market rages across several fronts, one combatant is ahead in a key battleground - control of the narrative.
“If you ask most people who’s winning hearts and minds right now, their instinctive answer is Lilly,” according to US-based healthcare communications expert, Kieran Fagan. And having analysed the messages that Eli Lilly and Novo Nordisk are sending about their products, Fagan says the data backs that up.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.